Related Experiment Video
Updated: May 8, 2026
A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
Published on: November 10, 2008
Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects
Steven P Millard1, Franziska Lutz, Ge Li
1Northwest Network VISN-20 Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA.
Abstract:
Low cerebrospinal fluid (CSF) Aβ(42) levels correlate with increased brain Aβ deposition in Alzheimer's disease (AD), which suggests a disruption in the degradation and clearance of Aβ from the brain. In addition, APOE ε4 carriers have lower CSF Aβ(42) levels than non-carriers. The hypothesis of this investigation was that CSF Aβ(42) levels would correlate with regulatory region variation in genes that are biologically associated with degradation or clearance of Aβ from the brain. CSF Aβ(42) levels were tested for associations with Aβ degradation and clearance genes and APOE ε4. Twenty-four SNPs located within the 5' and 3' regions of 12 genes were analyzed. The study sample consisted of 99 AD patients and 168 cognitively normal control subjects. CSF Aβ(42) levels were associated with APOE ε4 status in controls but not in AD patients; A2M regulatory region SNPs were also associated with CSF Aβ(42) levels in controls but not in AD patients, even after adjusting for APOE ε4. These results suggest that genetic variation within the A2M gene influences CSF Aβ(42) levels.
Insights
Genetic variations in the A2M gene may influence cerebrospinal fluid (CSF) levels of amyloid-beta 42 (Aβ(42)), a key marker in Alzheimer's disease (AD) pathology. This suggests A2M plays a role in Aβ clearance.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Low cerebrospinal fluid (CSF) amyloid-beta 42 (Aβ(42)) levels are linked to increased brain Aβ deposition in Alzheimer's disease (AD).
- APOE ε4 carriers exhibit lower CSF Aβ(42) levels compared to non-carriers, indicating a potential genetic influence on Aβ metabolism.
- Aβ clearance and degradation pathways are crucial in AD pathogenesis and are potential targets for therapeutic intervention.
Purpose of the Study:
- To investigate the association between CSF Aβ(42) levels and genetic variations in regulatory regions of genes involved in Aβ degradation and clearance.
- To examine the relationship between CSF Aβ(42) levels, APOE ε4 status, and specific gene polymorphisms.
Main Methods:
- Analysis of 24 single nucleotide polymorphisms (SNPs) in the 5' and 3' regulatory regions of 12 Aβ-related genes.
- Genotyping and measurement of CSF Aβ(42) levels in 99 AD patients and 168 cognitively normal controls.
- Statistical analysis to assess correlations between CSF Aβ(42), APOE ε4 status, and identified SNPs.
Main Results:
- CSF Aβ(42) levels showed an association with APOE ε4 status in control subjects, but not in AD patients.
- Regulatory region single nucleotide polymorphisms (SNPs) in the A2M gene were associated with CSF Aβ(42) levels in controls, independent of APOE ε4 status.
- No significant associations were found between CSF Aβ(42) levels and other tested gene variations or in AD patients.
Conclusions:
- Genetic variations within the A2M gene appear to influence CSF Aβ(42) levels, particularly in non-demented individuals.
- These findings suggest a potential role for A2M in the regulation of Aβ levels and its implications in Alzheimer's disease.
- Further research is warranted to elucidate the precise mechanisms by which A2M genetic variations affect Aβ metabolism.
